Candriam Investors has expanded its Brussels-based biotech equity strategy team with the appointment of Servaas Michielssens as senior biotechnology analyst.
Michielssens spent the last two years at the Max Planck Institute in Germany, where he developed computational protocols serving research of biomolecules with improved properties. He holds a Master in Computational Chemistry and a PhD in Science from the KU Leuven.
Based in Brussels, he will now be in charge of analysing the latest trends on drugs that are being developed for the $500bn Candriam Equities L Biotechnology fund.
“Servaas Michielssens had great knowledge of small molecule drug development and this is complementary with the other team members who are more protein drug specialists”, comments Rudi Van den Eynde, head of Thematic Global Equity at Candriam.